Christopher A Warlick

Christopher A Warlick is a Professor and Head of the Department of Urology at the University of Minnesota Medical School. He is a leading expert in prostate and bladder cancer, with a strong focus on cancer screening, prevention, active surveillance, and novel therapeutic strategies including focal and immune-mediated treatments.

Research Interests:

• Prostate Cancer Etiology and Survivorship
• Bladder Cancer Management
• Active Surveillance and Risk Stratification
• Minimally Invasive and Focal Therapies
• Transurethral Ablation Techniques
• Immunotherapy for Advanced Prostate Cancer

His recent publications reflect a consistent and impactful research trajectory, emphasizing clinical trials, surgical outcomes, and innovative diagnostics. Themes include comparative effectiveness of robotic vs open surgery, microbiome implications in prostate cancer, and AI-driven therapeutic development. His work bridges clinical practice and translational research, with strong industry and multi-institutional collaborations.

Scientific Awards and Recognition:

Advising and Grants: Dr. Warlick serves as Principal Investigator on multiple funded research projects, including a Phase II randomized trial (HEAT study), a multicenter ablation pilot, and an AI-designed mini-protein project funded by the U.S. Department of Defense. He collaborates with institutions such as Johns Hopkins University and industry partners including MacroGenics Inc., Francis Medical, Inc., and Photocure Inc. While formal student advisees are not listed, his role as PI indicates mentorship of junior researchers and clinical fellows.

Labs and Research Teams: Dr. Warlick leads a multidisciplinary research team focused on urologic oncology, with active projects spanning from early detection to advanced therapeutics. His work is supported by a robust network of clinical collaborators, bioengineers, and data scientists, particularly in the areas of imaging, immunotherapy, and surgical innovation.